Heidelberg Engineering announced the FDA has cleared the Spectralis OCT angiography (OCTA) module with Shift technology, which halves the device’s previous image acquisition time.
Available exclusively on third-generation Spectralis devices, Shift maintains data integrity and improves performance, thanks to a more powerful OCT engine, updated graphics processing technology and software optimisation, said the company. “Both the 85kHz preset for structural OCT and the 125kHz preset for OCTA allow eyecare practitioners to complete their patient exams more efficiently. Furthermore, the 125kHz OCTA image acquisition rate allows for visualisation of flow, even in miniscule vessels, while minimising artefacts, resulting in sharp and detailed images of the capillary network.”
Ram Liebenthal, Heidelberg’s general manager US said “… the next generation of OCTA … increases the acquisition speed without sacrificing image quality, thus making it a more versatile clinical tool in the diagnoses and management of retinal diseases.”
In related news, EssilorLuxottica has completed acquisition of an 80% stake in Heidelberg Engineering.
The agreement represents a step forward in EssilorLuxottica’s strategy and its med-tech journey, said the companies in a joint statement. “With a presence in over 100 countries, for more than three decades Heidelberg Engineering has been a reference in early detection of sight-threatening conditions such as glaucoma and age-related macular degeneration,” they said.
